• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Surprise Enhertu rejection follows NICE process change

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 05, 2024 at 11:42: AM
via NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.

article source
 

<



Similar threads

cafead
ESMO: AstraZeneca stands by Truqap despite surprise breast cancer flop
Replies
0
Views
13
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Elevar, Hengrui eye quick refile for PD-1 liver cancer combo after surprise FDA rejection
Replies
0
Views
21
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study
Replies
0
Views
90
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Lilly’s Donanemab Hit with Surprise Delay, Set to Face FDA Adcomm
Replies
0
Views
142
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Moderna posts surprise quarterly profit as it eyes RSV vaccine approval
Replies
0
Views
232
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote